Integrative hierarchical ensemble clustering for improved disease subtype discovery

2021 ◽  
Author(s):  
Bastian Pfeifer ◽  
Andrei Voicu-Spineanu ◽  
Michael G. Schimek ◽  
Nikolaos Alachiotis
Keyword(s):  
Ensemble Clustering ◽  
Disease Subtype

Identifying manufacturing operational conditions by physics-based feature extraction and ensemble clustering

2021 ◽  
Vol 60 ◽  
pp. 162-175
Author(s):  
Shenghan Guo ◽  
Mengfei Chen ◽  
Amir Abolhassani ◽  
Rajeev Kalamdani ◽  
Weihong Grace Guo
Keyword(s):  
Feature Extraction ◽  
Ensemble Clustering ◽  
Operational Conditions

scholarly journals Drosophila RASopathy Models Identify Disease Subtype Differences and Biomarkers of Drug Efficacy

iScience ◽  
2021 ◽  
pp. 102306
Author(s):  
Tirtha K. Das ◽  
Jared Gatto ◽  
Rupa Mirmira ◽  
Ethan Hourizadeh ◽  
Dalia Kaufman ◽  
...  
Keyword(s):  
Drug Efficacy ◽  
Disease Subtype ◽  
Subtype Differences

scholarly journals Stratified Feature Sampling for Semi-Supervised Ensemble Clustering

IEEE Access ◽  
2019 ◽  
Vol 7 ◽  
pp. 128669-128675 ◽  
Author(s):  
Jialin Tian ◽  
Yazhou Ren ◽  
Xiang Cheng
Keyword(s):  
Ensemble Clustering

scholarly journals Sporadic C reutzfeldt– J akob disease subtype‐specific alterations of the brain proteome: Impact on R ab3a recycling

PROTEOMICS ◽  
2012 ◽  
Vol 12 (23-24) ◽  
pp. 3610-3620 ◽  
Author(s):  
Joanna Gawinecka ◽  
Franco Cardone ◽  
Abdul R. Asif ◽  
Angela De Pascalis ◽  
Wiebke M. Wemheuer ◽  
...  
Keyword(s):  
Disease Subtype ◽  
Brain Proteome ◽  
The Brain

An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis

2011 ◽  
Vol 70 (6) ◽  
pp. 1115-1121 ◽  
Author(s):  
Veronica Codullo ◽  
Helen M Baldwin ◽  
Mark D Singh ◽  
Alasdair R Fraser ◽  
Catherine Wilson ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Mononuclear Cells ◽  
Platelet Rich Plasma ◽  
Critical Role ◽  
Serum Levels ◽  
Pcr Analysis ◽  
Peripheral Blood Mononuclear ◽  
Matrix Deposition ◽  
Disease Subtype ◽  
Inflammatory Chemokines

ObjectivesSystemic sclerosis (SSc) is characterised by vasculopathy, an aberrantly activated immune system and excessive extracellular matrix deposition. Inflammatory chemokines control migration of cells to sites of tissue damage; their removal from inflamed sites is essential for resolution of the inflammatory response. The atypical chemokine receptor D6 has a critical role in this physiological balance. To explore potential deregulation of this system in SSc, inflammatory chemokine and D6 expression were compared with that in healthy controls (HC).MethodsSerum levels of inflammatory mediators were assessed by luminex analysis. Peripheral blood mononuclear cells (PBMCs) were used in molecular and immunocytochemical analysis. Platelet-rich plasma was collected and assessed by western blotting for D6 expression levels. Sex-matched HC were used for comparison.Results72 patients with SSc and 30 HC were enrolled in the study. The chemokines MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4 and IL-8/CXCL8 were significantly increased in patients with SSc, regardless of disease subtype and phase. Quantitative PCR analysis revealed a significant 10-fold upregulation of D6 transcripts in patients with SSc compared with controls, and this was paralleled by increased D6 protein expression in the PBMCs of patients with SSc. Platelet lysates also showed strong D6 expression in patients with SSc but not in controls. Importantly, high levels of D6 expression correlated with reduced levels of its ligands in serum.ConclusionsInflammatory chemokines and the regulatory receptor D6 are significantly upregulated in SSc and high D6 levels are associated with lower systemic chemokine levels, indicating that some patients control systemic chemokine levels using D6. These results suggest that chemokines may represent a therapeutic target in SSc.

scholarly journals AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype?

2021 ◽  
Vol 42 (3) ◽  
pp. 863-869
Author(s):  
Jieni Zhang ◽  
Yin Chen ◽  
Jiaxin Chen ◽  
Xin Huang ◽  
Haiyan Wang ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Case Control Study ◽  
Southern China ◽  
Case Control ◽  
Disease Subtype ◽  
Bulbar Dysfunction ◽  
Control Study ◽  
Worse Prognosis ◽  
Distinct Subtype ◽  
Immunosuppressant Treatment

Abstract Introduction This study investigated the characteristics of double-seropositive myasthenia gravis (DSP-MG) in southern China for disease subtype classification. Methods A case-control study was carried out in which the characteristics of DSP-MG patients (n = 17) were compared to those of muscle-specific tyrosine kinase antibody-positive (MuSK)-MG and acetylcholine receptor antibody-positive (AChR)-MG patients (n = 8 and 27, respectively). We also performed a literature review of DSP-MG patients. Results Compared to AChR-MG, DSP-MG had greater bulbar dysfunction (47.1% vs 18.6%, P = 0.04), higher incidence of myasthenia crisis (41.2% vs 14.8%, P = 0.04), more severe Myasthenia Gravis Foundation of America classification at maximum worsening, greater autoantibody abnormalities (70.6% vs 33.3%, P = 0.015), greater need for immunosuppressant treatment (58.8% vs 3.7%, P < 0.001), and worse prognosis with less remission (11.8% vs 55.6%, P = 0.001). There were no differences between DSP-MG and MuSK-MG patients. DSP-MG described in published reports was comparable to MuSK-MG. Discussion DSP-MG in southern China may be a subtype of MuSK-MG.

Sign in / Sign up

Export Citation Format

Share Document